Literature DB >> 11488612

2-methoxyestradiol does not inhibit superoxide dismutase.

R Kachadourian1, S I Liochev, D E Cabelli, M N Patel, I Fridovich, B J Day.   

Abstract

It has been reported in the literature that the endogenous estrogen metabolite 2-methoxyestradiol (2-ME) inhibits both manganese and copper,zinc superoxide dismutases (Mn and Cu,Zn SODs) and that this mechanism is responsible for 2-ME's ability to kill cancer cells. In fact, as demonstrated using several SOD assays including pulse radiolysis, 2-ME does not inhibit SOD but rather interferes with the SOD assay originally used. Nevertheless, as confirmed by aconitase inactivation measurements and lactate dehydrogenase release in human leukemia HL-60 cells, 2-ME does increase superoxide production in these cells and is more toxic than its non-O-methylated precursor 2-hydroxyestradiol. Other mechanisms previously suggested in the literature may explain 2-ME's ability to increase intracellular superoxide levels in tumor cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488612     DOI: 10.1006/abbi.2001.2455

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  18 in total

1.  Light-Activated Pharmaceuticals: Mechanisms and Detection.

Authors:  David Kessel; John Reiners
Journal:  Isr J Chem       Date:  2012-09-01       Impact factor: 3.333

Review 2.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 3.  Expanding roles of superoxide dismutases in cell regulation and cancer.

Authors:  Meixia Che; Ren Wang; Xiaoxing Li; Hui-Yun Wang; X F Steven Zheng
Journal:  Drug Discov Today       Date:  2015-10-19       Impact factor: 7.851

4.  Flavonoid-induced glutathione depletion: potential implications for cancer treatment.

Authors:  Remy Kachadourian; Brian J Day
Journal:  Free Radic Biol Med       Date:  2006-03-31       Impact factor: 7.376

Review 5.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

Review 6.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

7.  Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells.

Authors:  Qi Zhang; Yan Ma; Yue-Fang Cheng; Wen-Jie Li; Zhenzhong Zhang; Shao-Yu Chen
Journal:  Cancer Lett       Date:  2011-09-17       Impact factor: 8.679

8.  Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity.

Authors:  Aster Legesse-Miller; Irene Raitman; Erin M Haley; Albert Liao; Lova L Sun; David J Wang; Nithya Krishnan; Johanna M S Lemons; Eric J Suh; Elizabeth L Johnson; Benjamin A Lund; Hilary A Coller
Journal:  Mol Biol Cell       Date:  2012-08-08       Impact factor: 4.138

9.  Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells.

Authors:  Babu V Sajesh; Melanie Bailey; Zelda Lichtensztejn; Philip Hieter; Kirk J McManus
Journal:  Genetics       Date:  2013-09-03       Impact factor: 4.562

10.  Sulphamoylated 2-methoxyestradiol analogues induce apoptosis in adenocarcinoma cell lines.

Authors:  Michelle Visagie; Anne Theron; Thandi Mqoco; Warren Vieira; Renaud Prudent; Anne Martinez; Laurence Lafanechère; Annie Joubert
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.